The following is a summary of "Tenecteplase versus alteplase for acute stroke within 4·5 h of onset (ATTEST-2): a randomised, ...

Share on Pinterest A new study has found that between tenecteplase and alteplase treatment, the former leads to slightly better stroke recovery. Image credit: Mihajlo Ckovric/Stocksy. Ischemic ...

Alteplase is the only drug approved by the U.S. Food and Drug Administration (FDA) for ischemic stroke. Tenecteplase, a newer ...

It has now been 25 years since prourokinase was in the spotlight as a potential treatment for acute ischaemic stroke. In 1999, the PROACT-II randomised controlled trial compared intra-arterial ...

Purpose. The efficacy and safety of i.v. alteplase up to 4.5 hours after acute ischemic stroke (AIS) onset were evaluated. Summary. Stroke is the leading cause of disability in the elderly ...

The clot-buster tenecteplase is associated with a slightly higher likelihood of excellent recovery and reduced disability ...

The clot-buster tenecteplase is associated with a slightly higher likelihood of excellent recovery and reduced disability three months following a stroke, compared to the drug alteplase ...

Tenecteplase is a genetically modified version of alteplase with a higher specificity ... if there may be a path forward for tenecteplase in stroke." Also included in the latest cull is RG6358 ...

a result that is consistent with several previous trials with other thrombolytics (alteplase or tenecteplase) in mild stroke, including PRISMS, ARAMIS, and TEMPO-2. Hill said this trial provided ...

In new guidance, NICE has cleared NHS use of Boehringer Ingelheim's clot-busting therapy Metalyse as a treatment for acute ischaemic stroke in adults. The healthcare cost-effectiveness watchdog ...